Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (21937)	6/6/1998 5:45:00 PM
From: Henry Niman	Respond to of 32384

Greg, As I said earlier, the entire Biotech therapeutics area is fair game (and I think that is why DR sees LGND's STAT effort increasing to 50% of their total effort). Most Biotechs target interferons, interleukins, or growth factors as therapeutic agents. LGND has shown that a tiny molecule can mimic the effects of the much larger proteins (polypeptide hormones). The small molecules can be tinkered with extensively (by organic chemists) at a low cost but high throughput 9and of course they can be taken orally). The discovery opens up a whole new approach. Most did not think that such an approach was feasible. The upcoming Science paper will create quite a bit of excitement in the scientific community and the big boys (pharmas) will take note. I still suspect that SBH downplayed the combination of genomics with combinatorial chemistry because this new approach is so powerful and the appropriate gene products (ligand and receptor combinations) are well known.